- Trials with a EudraCT protocol (2,017)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
2,017 result(s) found.
Displaying page 32 of 101.
EudraCT Number: 2012-004867-38 | Sponsor Protocol Number: NN7999-3895 | Start Date*: 2015-06-08 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Safety and Efficacy of nonacog beta pegol (N9-GP) in Previously Untreated Patients with Haemophilia B An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and ... | |||||||||||||
Medical condition: Haemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) ES (Ongoing) RO (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003136-25 | Sponsor Protocol Number: CTD-TCNPC-301 | Start Date*: 2021-10-25 | |||||||||||
Sponsor Name:Cyclo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Double blind, Randomized, Placebo controlled, Parallel group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl β cycl... | |||||||||||||
Medical condition: Niemann Pick Disease Type C1 | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) PL (Ongoing) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004228-41 | Sponsor Protocol Number: C0251002 | Start Date*: 2021-07-28 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | |||||||||||||
Medical condition: Dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) HU (Completed) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003467-26 | Sponsor Protocol Number: NN7769-4516 | Start Date*: 2021-11-30 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Safety, efficacy and exposure of subcutaneously administered NNC0365-3769 (Mim8) prophylaxis in children with haemophilia A with or without FVIII inhibitors | ||||||||||||||||||
Medical condition: Haemophilia A Haemophilia A with inhibitors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) PL (Ongoing) IT (Ongoing) ES (Ongoing) PT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003333-11 | Sponsor Protocol Number: AG348-C-023 | Start Date*: 2022-04-25 | |||||||||||
Sponsor Name:Agios Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Not Regular... | |||||||||||||
Medical condition: Pyruvate Kinase Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Ongoing) FR (Ongoing) IT (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004124-10 | Sponsor Protocol Number: 68284528MMY2003 | Start Date*: 2020-08-07 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) BE (Ongoing) ES (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004786-25 | Sponsor Protocol Number: AC-077A301 | Start Date*: 2019-09-05 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of maciten... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) PL (Ongoing) ES (Ongoing) BG (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002491-10 | Sponsor Protocol Number: Alofisel-4001 | Start Date*: 2020-03-10 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn’s Disease and Complex Perianal Fistula | |||||||||||||
Medical condition: Perianal fistulising Crohn´s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) ES (Ongoing) DE (Ongoing) FR (Ongoing) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003855-40 | Sponsor Protocol Number: MOR208C115 | Start Date*: 2022-03-09 | |||||||||||
Sponsor Name:MorphoSys AG | |||||||||||||
Full Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Ref... | |||||||||||||
Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) AT (Ongoing) CZ (Ongoing) IT (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000050-26 | Sponsor Protocol Number: AV-951-20-304 | Start Date*: 2021-11-11 | |||||||||||
Sponsor Name:AVEO Pharmaceuticals, Inc. | |||||||||||||
Full Title: TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have... | |||||||||||||
Medical condition: Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) CZ (Ongoing) BE (Ongoing) PL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003680-10 | Sponsor Protocol Number: AROAPOC3-3001 | Start Date*: 2022-01-13 | |||||||||||
Sponsor Name:Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome | |||||||||||||
Medical condition: Familial Chylomicronemia Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) IE (Ongoing) BE (Ongoing) ES (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001829-40 | Sponsor Protocol Number: 201 | Start Date*: 2019-01-02 | |||||||||||
Sponsor Name:Y-mAbs Therapeutics A/S | |||||||||||||
Full Title: A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete... | |||||||||||||
Medical condition: Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Ongoing) ES (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003733-38 | Sponsor Protocol Number: ORP-TMZ-I-b | Start Date*: 2021-11-27 | |||||||||||||||||||||||||||||||
Sponsor Name:ORPHELIA Pharma | |||||||||||||||||||||||||||||||||
Full Title: TEMOkids study (ORP-TMZ-I- b): A Population pharmacokinetic, acceptability and safety study for KIMOZO, a paediatric oral suspension of temozolomide | |||||||||||||||||||||||||||||||||
Medical condition: Different pediatric cancers such as malignant glioma and also relapsed or refractory neuroblastoma, rhabdomyosarcoma, medulloblastoma, and Ewing sarcoma, for which treatment with the cytotoxic tem... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) ES (Ongoing) NL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002987-29 | Sponsor Protocol Number: BT–L-CsA–303–FU | Start Date*: 2020-02-12 | |||||||||||
Sponsor Name:Zambon SpA | |||||||||||||
Full Title: An Open Label Follow-Up Study to Evaluate the Long Term Safety and Efficacy of L-CSA in Patients with a Diagnosis of CLAD-BOS after they have completed the participation to BOSTON 1 and BOSTON 2 st... | |||||||||||||
Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Single or post Double Lung Transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) AT (Ongoing) FR (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006226-49 | Sponsor Protocol Number: NN6019-4940 | Start Date*: 2022-08-18 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM) | |||||||||||||
Medical condition: Transthyretin amyloid cardiomyopathy (ATTR CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) PT (Ongoing) DE (Ongoing) CZ (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000824-36 | Sponsor Protocol Number: HLSC-UCD-01 | Start Date*: 2021-12-09 | |||||||||||
Sponsor Name:Unicyte AG | |||||||||||||
Full Title: An open-label, controlled, multi-site, Phase I clinical trial to assess the ureagenesis capacity in newborns and infants up to the age of 12 months with neonatal and infantile onset of urea cycle d... | |||||||||||||
Medical condition: Subject has a genetically confirmed diagnosis of any of the following urea cycle disorders: ASS, CPS1, ASL, OTC Subjects without UCD can have other stable illness that not interfere with the clini... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) AT (Prematurely Ended) IT (Ongoing) BE (Completed) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006781-21 | Sponsor Protocol Number: COAV101A12308 | Start Date*: 2022-10-31 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: Long-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials | |||||||||||||
Medical condition: Spinal Muscular Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) DE (Ongoing) DK (Ongoing) ES (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000211-23 | Sponsor Protocol Number: AG348-C-017 | Start Date*: 2021-10-15 | |||||||||||
Sponsor Name:Agios Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENE... | |||||||||||||
Medical condition: Non–Transfusion-Dependent Alpha- or Beta-Thalassemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DK (Ongoing) IT (Ongoing) BG (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000212-34 | Sponsor Protocol Number: AG348-C-018 | Start Date*: 2021-10-11 | |||||||||||
Sponsor Name:Agios Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZ... | |||||||||||||
Medical condition: Transfusion-Dependent Alpha- or Beta-Thalassemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DK (Ongoing) IT (Ongoing) BG (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001992-35 | Sponsor Protocol Number: MS200647_0055 | Start Date*: 2020-04-30 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Merck Healthcare KGaA | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp alfa (M7824) as First-line Treatment of Biliary Tract Cancer | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Biliary Tract Cancer | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) FR (Prematurely Ended) PL (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
